Tauriga Sciences Inc (OTCMKTS:TAUG) is on the rise accompanied by an increase in trading volume. The stock has a long history of nice moves running the last time from under a nickel to over $0.35 in May of 2019.
TAUG move up comes after the Company reported meaningful progress in the development of its pharmaceutical grade version of Tauri-Gum™. TAUG has retained the law-firm of Lowenstein Sandler to represent it, in connection with regulatory matters related to this proposed pharmaceutical product development. TAUG is working directly with the heads of the Firm’s FDA Practice, Chemicals & Life Sciences Patent Practice, and Life Sciences Group.
Tauriga Sciences Inc (OTCMKTS:TAUG) bills itself as a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities. One such opportunity on which the Company has acted, involves the Company having entered into the cannabidiol infused chewing gum product business. This CBD infused chewing gum product has been branded under the following name: Tauri-Gum™. The Company is currently in production of three distinct flavors of Tauri-Gum™: MINT, BLOOD ORANGE, and POMEGRANATE. On December 6, 2019 the Company announced that it completed the initial production run with the introduction of a 25mg Vegan CBD Isolate Infused vegan gummy, branded under the name: Tauri-Gummies™.
TAUG has also announced the development of a Cannabigerol Isolate infused version of Tauri-Gum™. The flavor that has been selected is Starfruit/Peach and each piece of gum will contain 10mg of CBG Isolate / Each blister pack will contain 80mg of CBG Isolate. The Company expects to commence production during its 4thFiscal Quarter of 2020 (January 1, 2020 – March 31, 2020). TAUG also recently launched its E-Commerce site – taurigum.com
To Find out the inside Scoop on TAUG Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Microcapdaily has been reporting on TAUG for years stating back on November 4, 2014 on TAUG – Tauriga Sciences Inc recently saw a significant increase in interest and a nice pop as the entire Marijuana sector heats up again. TAUG is a stock with a history of highly explosive moves running from sub pennies to over a dime the last time pot stocks heated up. The stock collapsed with the rest of the sector in March when CANN got halted and has been drifting downward in recent months. With medical Marijuana legalized in Alaska, Oregon and Washington DC (besides Colorado and Washington where it was already legal) many investors are predicting the massive resulting publicity may once again drive pot stocks sky high and TAUG seems like the perfect trade opportunity to cash in on the trend.
On February 18 TAUG reported meaningful progress in the development of its pharmaceutical grade version of Tauri-Gum™. On January 13, 2020, the Company announced the formation of a wholly owned subsidiary, “Tauriga Pharma Corporation,” to reflect the ongoing development of a pharmaceutical Nausea Regulation “Anti-Nausea” product. The Company has finalized the formulation for this proposed pharmaceutical grade version of Tauri-Gum™ and is now focused on securing Intellectual Property as well as holding discussions with the FDA”. The Company has retained the law-firm of Lowenstein Sandler (the “Firm”) to represent it, in connection with regulatory matters related to this proposed pharmaceutical product development. The Company is working directly with the heads of the Firm’s FDA Practice, Chemicals & Life Sciences Patent Practice, and Life Sciences Group.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $5.6 million market valuation TAUG is fully reporting OTCBB and has very little debt and growing revenues reporting $200k in sales for the 9 months ended, December 31, 2019. TAUG is an exciting story developing in small caps; the Company markets its CBD infused chewing gum branded under the name: Tauri-Gum™ and is currently in production of three flavors: MINT, BLOOD ORANGE, and POMEGRANATE. TAUG also just announced meaningful progress in the development of its pharmaceutical grade version of Tauri-Gum™ and retained the law-firm of Lowenstein Sandler to represent it, in connection with regulatory matters related to this proposed pharmaceutical product development. We will be updating on TAUG when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with TAUG.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in TAUG either long or short and we have not been compensated for this article.